Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dore-Duffy, P.
Right arrow Articles by Perry, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dore-Duffy, P.
Right arrow Articles by Perry, W.
NEUROLOGY 1986;36:1587
© 1986 American Academy of Neurology

Prostaglandin release in multiple sclerosis

Correlation with disease activity Paula Dore-Duffy, James O. Donaldson, Tracey Koff, Michael Longo and William Perry

Multiple Sclerosis Center, Division of Neuroimmunology, Department of Neurology. University of Connecticut Health Center Farmington, CT.

Release of prostaglandin E (PGE) was examined in leukocyte cultures from patients with definite MS who had had at least one recent exacerbation, others with chronic progressive or stable MS, and healthy controls. MS patients had higher baseline levels of PGE than did controls. Patients with active symptoms exhibited a sharp increase in PGE release early in or just before the onset of clinical symptoms. Levels dropped early in exacerbation immediately after the burst in PGE synthesis activity. Values gradually increased to control levels and then to preexacerbation levels. Similar rises and falls were not seen in stable MS. MS patients may have a circulating population of activated leukocytes that produce PGE.

Address correspondence and reprint requests to Dr. Dore-Duffy, Multiple Sclerosis Center. Division of Neuroimmunology Department of Neurology University of Connecticut Health Center, Farmington, CT 06032.

Supported in part by a grant from the National Multiple Sclerosis Society and NIH grant no. NS14357.

Accepted for publication March 18. 1986.




This article has been cited by other articles:


Home page
 CVIHome page
R. Balabanov, D. Lisak, T. Beaumont, R. P. Lisak, and P. Dore-Duffy
Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)
Clin. Vaccine Immunol., November 1, 2001; 8(6): 1196 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A. T Reder, K. Genc, P. V Byskosh, and A. M. Porrini
Monocyte activation in multiple sclerosis
Multiple Sclerosis, June 1, 1998; 4(3): 162 - 168.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. A. Rudick and R. M. Ransohoff
Cytokine Secretion by Multiple Sclerosis Monocytes: Relationship to Disease Activity
Arch Neurol, March 1, 1992; 49(3): 265 - 270.
[Abstract] [PDF]